Last reviewed · How we verify
Arm 1: CL-H1T
CL-H1T is a compound that targets the kappa opioid receptor.
CL-H1T is a compound that targets the kappa opioid receptor. Used for Chronic pain.
At a glance
| Generic name | Arm 1: CL-H1T |
|---|---|
| Also known as | sumatriptan succinate 90mg/promethazine HCl 18.75mg, sumatriptan succinate 90mg/promethazine HCl 37.5mg |
| Sponsor | Charleston Laboratories, Inc |
| Drug class | kappa opioid receptor agonist |
| Target | kappa opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
CL-H1T works by binding to the kappa opioid receptor, which is involved in pain modulation. This binding leads to a reduction in pain perception. CL-H1T's mechanism of action is similar to other kappa opioid receptor agonists.
Approved indications
- Chronic pain
Common side effects
- Nausea
- Vomiting
- Dizziness
Key clinical trials
- A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm 1: CL-H1T CI brief — competitive landscape report
- Arm 1: CL-H1T updates RSS · CI watch RSS
- Charleston Laboratories, Inc portfolio CI